| [1] | Li, W., Wu, H., Han, Y., Wu, H., Lin, Z., & Zhang, B. (2023). Global status and trends in gout research from 2012 to 2021: A bibliometric and visual analysis. Clinical Rheumatology, 42(5), 1371–1388. |
| |
| [2] | Caron, J. P., Kreher, M. A., Mickle, A. M., Wu, S., Przkora, R., Estores, I. M., & Sibille, K. T. (2022). Intermittent fasting: Potential utility in the treatment of chronic pain across the clinical spectrum. Nutrients, 14(12), 2536. |
| |
| [3] | Petridou, G. (2023). Pain with a PR problem: Narrating gout-induced pain in the Second Sophistic. In J. Clarke, D. King, & H. Baltussen (Eds.), Pain narratives in Greco-Roman writings: Studies in the representation of physical and mental suffering (pp. 121–144). Brill. |
| |
| [4] | Singh, M., Gupta, P., & Reddy, L. (2022). Hyperuricemia screening camp data: Prevalence and associated risk factors. Journal of Metabolic Syndrome, 12(4), 287–294. |
| |
| [5] | Patel, R., Sharma, A., & Kumar, S. (2023). Prevalence of hyperuricemia in the Indian population: A systematic review. Indian Journal of Public Health, 67(2), 123–135. |
| |
| [6] | Choi, H. K., &Curhan, G. (2007). Independent impact of gout on mortality and risk for coronary heart disease. Circulation, 116(8), 894 900. |
| |
| [7] | Feig, D. I., Kang, D. H., & Johnson, R. J. (2008). Uric acid and cardiovascular risk. New England Journal of Medicine, 359(17), 1811- 1821. |
| |
| [8] | Bove, M., Cicero, A. F. G., Veronesi, M., & Borghi, C. (2017). An evidence-based review on urate-lowering treatments: Implications for optimal treatment of chronic hyperuricemia. Vascular Health and Risk Management, 13, 23–28. |
| |
| [9] | Borghi, C., Agabiti-Rosei, E., Johnson, R. J., Kielstein, J. T., Lurbe, E., Mancia, G., Redon, J., Stack, A. G., &Tsioufis, K. P. (2020). Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. European Journal of Internal Medicine, 80, 1–11. |
| |
| [10] | Kuwabara, M., Hisatome, I., Ae, R., Kosami, K., Aoki, Y., Andres-Hernando, A., Kanbay, M., &Lanaspa, M. A. (2025). Hyperuricemia: A new cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases, 35(3), 103796. |
| |
| [11] | Kim, I. Y., Han, K. D., Kim, D. H., Eun, Y., Cha, H. S., Koh, E. M., Lee, J., & Kim, H. (2019). Women with metabolic syndrome and general obesity are at a higher risk for significant hyperuricemia compared to men. Journal of Clinical Medicine, 8(6), 837. |
| |
| [12] | Puig, J. G., & Martinez, M. A. (2008). Hyperuricemia, gout, and the metabolic syndrome. Current Opinion in Rheumatology, 20(2), 187- 191. |
| |
| [13] | Gong, M., Wen, S., Nguyen, T., Wang, C., Jin, J., & Zhou, L. (2020). Converging relationships of obesity and hyperuricemia with special reference to metabolic disorders and plausible therapeutic implications. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 943–962. |
| |
| [14] | Choi, H. K., & Ford, E. S. (2007). Prevalence of the metabolic syndrome in individuals with hyperuricemia. The American Journal of Medicine, 120(5), 442–447. |
| |
| [15] | Chen, H. S. (2011). Clinical implications of the metabolic syndrome and hyperuricemia. Journal of the Chinese Medical Association, 74(12), 527 528. |
| |
| [16] | Billiet, L., Doaty, S., Katz, J. D., & Velasquez, M. T. (2014). Review of hyperuricemia as new marker for metabolic syndrome. International Scholarly Research Notices, 2014(1), 852954. |
| |
| [17] | Lee, J. M., Kim, H. C., Cho, H. M., Oh, S. M., Choi, D. P., & Suh, I. (2012). Association between serum uric acid level and metabolic syndrome. Journal of Preventive Medicine and Public Health, 45(3), 181–187. |
| |
| [18] | Wu, J., Qiu, L., Cheng, X., Xu, T., Wu, W., Zeng, X., Ye, Y., & Li, Y. (2017). Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population. Scientific Reports, 7(1), 5456. |
| |
| [19] | Roman, Y. M. (2022). Moving the needle in gout management: The role of culture, diet, genetics, and personalized patient care practices. Nutrients, 14(17), 3590. |
| |
| [20] | Alberti, K. G., & Zimmet, P. Z. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine, 15(7), 539–553. |
| |
| [21] | Grundy, S. M., Brewer, H. B., Jr, Cleeman, J. I., Smith, S. C., Jr, &Lenfant, C. (2004). Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 109(3), 433–438. |
| |
| [22] | Ford, E. S., Giles, W. H., & Dietz, W. H. (2002). Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA, 287(3), 356–359. |
| |
| [23] | Krishnan, E., Chen, L., & Schumacher, H. R. (2006). Hyperuricemia and incident hypertension among men with gout. Hypertension, 48(1), 28–33. |
| |
| [24] | Nakanishi, N., Tatara, K., Okamoto, M., Matsuo, H., & Ueshima, H. (2003). Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. European Journal of Epidemiology, 18(6), 523–529. |
| |